search
Back to results

Prevalence of HCV in HIV-negative MSM

Primary Purpose

Hepatitis C Virus Infection

Status
Unknown status
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
HCV IgG test
Sponsored by
Erasmus Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Hepatitis C Virus Infection

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Self-identifying as a man-who-has-sex-with-men (MSM)
  • Willing to undergo HCV testing

Exclusion Criteria:

  • Clients known to be HIV positive

Sites / Locations

  • GGD Rotterdam RijnmondRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Testing for HCV

Arm Description

HCV IgG test and questionnaire; both at visit to the sexual health clinic

Outcomes

Primary Outcome Measures

HCV antibody prevalence
Percentage of HCV IgG antibody positive clients per 1000 HIV-negative MSM tested
Value of HCV-MOSAIC risk score in HIV-negative MSM
Assess risk factors for a positive HCV IgG test in the study population according to the HCV-MOSAIC risk score, using sexual behavior questionnaires. The HCV-MOSAIC risk score is validated to identify HIV+MSM at risk for an acute HCV infection (Newsum et al, 2017). HCV-MOSAIC risk score: Condomless receptive anal intercourse in the last 6 months - 1.1 Sharing of sex toys in the last 6 months - 1.2 Unprotected fisting in the last 6 months - 0.9 Injecting drug use in the last 12 months - 1.4 Sharing of straws when using nasally administered drug in the last 12 months - 1.0 Ulcerative STI in the last 12 months - 1.4 Cut-off sum ≥2.0 = at risk for acute HCV infection

Secondary Outcome Measures

HCV infection prevalence
Prevalence of active HCV infection (RNA positive) among those with HCV IgG antibodies
Proportion participating in study
Percentage of HIV-negative MSM that accepted to be tested for HCV

Full Information

First Posted
June 25, 2019
Last Updated
January 27, 2020
Sponsor
Erasmus Medical Center
Collaborators
Public Health Service of Rotterdam-Rijnmond
search

1. Study Identification

Unique Protocol Identification Number
NCT04005248
Brief Title
Prevalence of HCV in HIV-negative MSM
Official Title
Prevalence of Undiagnosed HCV Infections in HIV-negative MSM Visiting a Sexual Health Clinic.
Study Type
Interventional

2. Study Status

Record Verification Date
January 2020
Overall Recruitment Status
Unknown status
Study Start Date
October 1, 2019 (Actual)
Primary Completion Date
December 31, 2022 (Anticipated)
Study Completion Date
June 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Erasmus Medical Center
Collaborators
Public Health Service of Rotterdam-Rijnmond

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study measures the prevalence of undiagnosed hepatitis C virus (HCV) infection in HIV-negative men-who-have-sex-with-men (MSM) visiting the sexual health clinics of public health services (in dutch: gemeentelijke gezondheidsdienst, GGD), in order to evaluate if systematic screening for HCV of HIV-negative MSM attending sexual health clinics in the Netherlands is needed.
Detailed Description
Until recently, sexually acquired HCV infections were thought to be limited to HIV-positive MSM. Yet, emerging data show that the prevalence of HCV among HIV uninfected MSM that opt-in for HIV pre-exposure prophylaxis (PrEP) is much higher. It was 5% (n=18/375) in Amsterdam and 2% (n=4/200) in Antwerp (Be-PrEP-ared; EudraCT2015-000054-37) (23). This observation may be the result of the fact that PrEP users are, by definition, at risk for sexually transmitted infections because PrEP is only prescribed to those at risk for HIV. However, another explanation may be that in the new context of HIV "treatment as prevention" and the availability of PREP as a way to protect oneself against HIV, the incidence of HCV in HIV uninfected MSM is changing. Furthermore, if PrEP use would lead to an increase in sexual risk-taking, this may eventually lead to an increase in the incidence of HCV among HIV negative MSM on PrEP. If these HCV infections among HIV negative MSM remain unnoticed, they are a continuous source of HCV infections in HIV+MSM as well for the larger HIV-MSM community. Furthermore, PrEP as well as the very well-documented efficacy of HIV treatment as prevention can be expected to increase sexual mixing of HIV- and HIV+MSM. Based on the observations described above, we hypothesize that undiagnosed HCV infections in HIV negative MSM are (or may become) an important source of HCV (re)infections in HIV+MSM as well as the larger HIV-MSM population. Primary objectives: Measure the prevalence of HCV in a large group of HIV-negative MSM attending sexual health clinics in the Netherlands. Assess Risk Factors for HCV in order to validate the HCV-MOSAIC risk score in HIV-MSM, which may allow for a more cost-effective (=targeted) HCV testing of HIV-MSM in the future Secondary objectives: Measure the acceptability of HCV testing in HIV-MSM at public health clinics. Evaluate the HCV outcome in terms of the proportion of HCV infections that cleared spontaneously (= HCV IgG positive but HCV RNA negative) versus the total number of HCV IgG positive clients. The HCV-immunoglobulin G (IgG) test is offered on top of the regular sexually transmitted infection (STI) tests. A positive HCV-IgG test will be followed by an HCV-RNA test. Clients known to be HCV IgG positive as a result of a previous HCV infection will be tested for HCV using an HCV-RNA test. Before HCV testing, participants will be asked to fill out a detailed study questionnaire about possible risk factors for HCV acquisition (PREP use, receptive unprotected anal intercourse, use of non-IV or injection drugs during sex, fisting, recent diagnosis of ulcerative rectal STI, etc.).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatitis C Virus Infection

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Cross-sectional study
Masking
None (Open Label)
Allocation
N/A
Enrollment
4000 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Testing for HCV
Arm Type
Other
Arm Description
HCV IgG test and questionnaire; both at visit to the sexual health clinic
Intervention Type
Diagnostic Test
Intervention Name(s)
HCV IgG test
Intervention Description
An HCV IgG test (performed on blood already collected for regular STI tests), combined with a questionnaire on sexual risk behavior. If client is HCV IgG positive, a HCV RNA test will be performed.
Primary Outcome Measure Information:
Title
HCV antibody prevalence
Description
Percentage of HCV IgG antibody positive clients per 1000 HIV-negative MSM tested
Time Frame
From start study to end of study, at least 2 years
Title
Value of HCV-MOSAIC risk score in HIV-negative MSM
Description
Assess risk factors for a positive HCV IgG test in the study population according to the HCV-MOSAIC risk score, using sexual behavior questionnaires. The HCV-MOSAIC risk score is validated to identify HIV+MSM at risk for an acute HCV infection (Newsum et al, 2017). HCV-MOSAIC risk score: Condomless receptive anal intercourse in the last 6 months - 1.1 Sharing of sex toys in the last 6 months - 1.2 Unprotected fisting in the last 6 months - 0.9 Injecting drug use in the last 12 months - 1.4 Sharing of straws when using nasally administered drug in the last 12 months - 1.0 Ulcerative STI in the last 12 months - 1.4 Cut-off sum ≥2.0 = at risk for acute HCV infection
Time Frame
From start study to end of study, at least 2 years
Secondary Outcome Measure Information:
Title
HCV infection prevalence
Description
Prevalence of active HCV infection (RNA positive) among those with HCV IgG antibodies
Time Frame
From start study to end of study, at least 2 years
Title
Proportion participating in study
Description
Percentage of HIV-negative MSM that accepted to be tested for HCV
Time Frame
From start inclusion to end of inclusion period, at least 1 year

10. Eligibility

Sex
Male
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Self-identifying as a man-who-has-sex-with-men (MSM) Willing to undergo HCV testing Exclusion Criteria: Clients known to be HIV positive
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Bart J.A. Rijnders, MD PhD
Phone
003110-7033510
Email
b.rijnders@erasmusmc.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Rosanne Verwijs, MD
Phone
00316-12725005
Email
n.verwijs@erasmusmc.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bart J.A. Rijnders, MD PhD
Organizational Affiliation
Erasmus Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
GGD Rotterdam Rijnmond
City
Rotterdam
Country
Netherlands
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
28657964
Citation
Hoornenborg E, Achterbergh RCA, Schim van der Loeff MF, Davidovich U, Hogewoning A, de Vries HJC, Schinkel J, Prins M, van de Laar TJW; Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam Initiative, MOSAIC study group. MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection. AIDS. 2017 Jul 17;31(11):1603-1610. doi: 10.1097/QAD.0000000000001522.
Results Reference
background
PubMed Identifier
26634219
Citation
Vanhommerig JW, Lambers FA, Schinkel J, Geskus RB, Arends JE, van de Laar TJ, Lauw FN, Brinkman K, Gras L, Rijnders BJ, van der Meer JT, Prins M; MOSAIC (MSM Observational Study of Acute Infection With Hepatitis C) Study Group; van der Meer JT, Molenkamp R, Mutschelknauss M, Nobel HE, Reesink HW, Schinkel J, van der Valk M, van den Berk GE, Brinkman K, Kwa D, van der Meche N, Toonen A, Vos D, van Broekhuizen M, Lauw FN, Mulder JW, Arends JE, van Kessel A, de Kroon I, Boonstra A, van der Ende ME, Hullegie S, Rijnders BJ, van de Laar TJ, Gras L, Smit C, Lambers FA, Prins M, Vanhommerig JW, van der Veldt W. Risk Factors for Sexual Transmission of Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men: A Case-Control Study. Open Forum Infect Dis. 2015 Aug 6;2(3):ofv115. doi: 10.1093/ofid/ofv115. eCollection 2015 Sep.
Results Reference
background
PubMed Identifier
28597832
Citation
Newsum AM, Stolte IG, van der Meer JT, Schinkel J, van der Valk M, Vanhommerig JW, Buve A, Danta M, Hogewoning A, Prins M; MOSAIC collaborators. Development and validation of the HCV-MOSAIC risk score to assist testing for acute hepatitis C virus (HCV) infection in HIV-infected men who have sex with men (MSM). Euro Surveill. 2017 May 25;22(21):30540. doi: 10.2807/1560-7917.ES.2017.22.21.30540.
Results Reference
background

Learn more about this trial

Prevalence of HCV in HIV-negative MSM

We'll reach out to this number within 24 hrs